Menu About Us >> Our Business >> Eurofins Fact Sheet Eurofins Fact Sheet Company overview Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research services. Eurofins is also one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, Biopharma Contract Development and Manufacturing, advanced material sciences and in the support of clinical studies. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products. History Eurofins Scientific was founded in 1987 with four employees to market the SNIF-NMRâ technology, a patented analytical method used to verify the origin and purity of several types of food and beverages and identify sophisticated fraud not detectable by other methods. Today, the Eurofins Group is a leading provider of testing and analytical services with: an international network of more than 900 laboratories in over 50 countries 55,000 staff a portfolio of over 200,000 analytical methods more than 450 million tests performed each year Eurofins recently joined the CAC 40 index and has been for over two decades one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ revenues have increased by 34% each year (in compound average) to over EUR 5.4 billion in 2020. Furthermore, between the Initial Public Offering on 24 October 1997 (EUR 0.183) and 30 June 2021 (EUR 96.40), Eurofins’ share price has multiplied by 527x, an annual average increase of 30% (against 4% for the SBF 120, 4% for the CAC 40, 7% for the S&P 500 and 10% for the NASDAQ over the same period). A commitment to innovation and sustainability Since its foundation, Eurofins has contributed significantly to the advancement of science through Testing for Life. We are proud of the discoveries and advancements our specialists have made in a myriad of sectors, ranging from food to pharma or forensics testing. Our laboratories around the world are helping to improve cancer treatments, fight the growing problem of antibiotic resistance, catch criminals, safeguard the health of bees, ensure our food and water is safe, indicate paternity, protect transplant patients’ lives and beat viruses like COVID-19. Whether we are helping to improve health outcomes, ensure food safety or determine environmental impact, sustainability is at the heart of our work. By its nature, our work helps corporations, organisations and governments improve their environmental and societal impact. On the ground, we are working to become carbon neutral by 2025 through reduction and offsetting of carbon emissions and the Eurofins Foundation is supporting charities and NGOs across the world, who share our goal to make the world a safer and healthier place for all. Recent developments Since 2020, the Group has risen to the challenges of COVID-19, quickly developing a very broad range of products and services critical to the management of COVID-19. It set up, at pace, significant scale testing capacity and remained at the forefront of both scientific and product innovation. The Group supported the development of vaccines by most leading providers. It also innovated to produce new critical tests and testing formats for the individual and the workplace and recently the GSD Novatype® RT-PCR for fast variant identification. It launched new testing formats for the individual, such as the GSD NovaPrime® SARS-CoV-2, successfully validated for pharynx gargle and saliva samples, as well as solutions for the workplace, such as the SAFER@WORK™ programmes, designed to help companies set up advanced risk management protocols to limit the impact of COVID-19, and Eurofins COVID-19 Sentinel™ waste water and environmental tests. The remaining business (excluding COVID-19 clinical testing and reagents revenues) demonstrated its resilience and delivered strong results in 2020 and in the first nine months of 2021. Laboratories of the Group continued to make scientific advances and innovations in multiple core business areas including the world’s first official method for the identification of fructans certified by the AOAC and ISO bodies, the world’s first AOAC Performance Tested MethodsSM status for a screening method to detect aflatoxin M1 in milk commodities, Viracor TRAC™, a proprietary donor-derived cell-free DNA assay for detection of acute kidney rejection and TruGraf Liver, a unique, non-invasive blood-based test to support liver transplant patients. Outlook The business outlook remains very strong in almost all our areas of activity. Eurofins’ focus on Testing for Life and investing for over 10 years to build a leading global position and unmatched state-of-the-art laboratory network is providing a solid foundation for strong profitable growth in the post pandemic times. It increasingly appears that the evolutions resulting from the pandemic should drive increasing demand for Eurofins’ services for many years to come. Going forward, Eurofins intends to continue to invest significantly to be the most digital and innovative member of its industry and participate meaningfully in the new markets opened by the many recent genomic, proteomic, and life sciences scientific breakthroughs. Eurofins Fact Sheet Eurofins Lab Directory Our Vision: To be the Global Leader in Testing for Life Our Mission: To contribute to a safer and healthier world by providing our customers with innovative and high quality laboratory, research and advisory services whilst creating opportunities for our employees and generating sustainable shareholder value Our Values: Achievement of our Mission is based on Eurofins "Core Values", which commit us to Customer Focus, Quality, Competence & Team Spirit and Integrity Eurofins shares are listed on Euronext Paris (since IPO in October 1997) ISIN FR0014000MR3, Euronext ERF, Reuters EUFI.PA, Bloomberg ERF FP Euronext Paris: EURONEXT 100, SBF 120, SBF TOP 80 EW, CAC ALL SHARES, CAC ALL-TRADABLE, CAC HEALTH CARE, CAC L60 RI SW, CAC LARGE 60, CAC LARGE 60 EW, CAC NEXT 20, EN H C EQ&SER EW. Euronext Amsterdam: EN CORE E100 EW, EN EUR N100 EW, EN EUROZONE 150 EW, EN EUROPE 500, EN EUROZONE 300, EN EZ L&M 60 EW. Other: MSCI Europe, STOXX Europe 600. Please refer to our on-line group directory for laboratory contact information *2020 and 2021 objectives include 5% organic growth and €200m annual revenues from acquisitions consolidated at mid-year in each of 2020 and 2021 (objectives are set at constant average 2019 FX rates). Homepage | Search | Careers | Press | Contact Us | Investors Sitemap | Cookie Notice | Terms and Conditions | Eurofins Global Cookie Preferences © Eurofins Scientific 2021 Last updated: Friday, December 3, 2021 About Cookies on This Site By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy Accept All Cookies Adjust Preferences